Last updated: February 18, 2026
This report analyzes the market landscape and projects future pricing for the drug identified by National Drug Code (NDC) 24208-0507. The analysis considers current market dynamics, patent expirations, and competitive pressures to forecast potential price trajectories.
What is NDC 24208-0507?
National Drug Code (NDC) 24208-0507 identifies a specific pharmaceutical product. Based on available data, this NDC is associated with Sildenafil Citrate Oral Suspension, 10 mg/mL, manufactured by Aurobindo Pharma USA, Inc.. [1] Sildenafil Citrate is a phosphodiesterase type 5 (PDE5) inhibitor. It is primarily used for the treatment of erectile dysfunction in men. It is also indicated for the treatment of pulmonary arterial hypertension (PAH) under the brand name Revatio. [2]
Current Market Status for Sildenafil Citrate
Sildenafil Citrate is a widely available generic medication. Its primary indication, erectile dysfunction (ED), represents a significant and established market.
Key Market Segments
- Erectile Dysfunction (ED): This is the largest market segment for Sildenafil Citrate. The prevalence of ED increases with age, and accessibility of generic Sildenafil has made it a common treatment option.
- Pulmonary Arterial Hypertension (PAH): While a smaller segment compared to ED, the use of Sildenafil (as Revatio) for PAH is medically significant.
Regulatory Landscape
Sildenafil Citrate is approved by the U.S. Food and Drug Administration (FDA) for its indicated uses. As a generic drug, it faces stringent bioequivalence requirements to demonstrate therapeutic equivalence to its branded counterparts.
Competitive Landscape
The market for Sildenafil Citrate is highly competitive.
- Branded Sildenafil (Viagra): Pfizer's Viagra was the original branded drug for ED. While still present, its market share has been significantly eroded by generics following patent expiry.
- Generic Sildenafil Manufacturers: Numerous pharmaceutical companies manufacture and market generic Sildenafil Citrate, including Aurobindo Pharma USA, Inc. (producer of NDC 24208-0507), Teva Pharmaceuticals, Mylan (now Viatris), and others. This has led to intense price competition.
- Other PDE5 Inhibitors: The market also includes other PDE5 inhibitors such as Tadalafil (Cialis) and Vardenafil (Levitra), which compete for market share within the ED segment.
Patent Expirations and Generic Entry
The original patents for Viagra (sildenafil citrate) expired in the late 2000s and early 2010s, paving the way for generic entry. This event significantly impacted pricing, leading to a substantial decrease in the average selling price for Sildenafil Citrate. [3] The patent expiry for Revatio (sildenafil citrate for PAH) also occurred, allowing for generic competition in this therapeutic area.
Pricing Dynamics and Projections for NDC 24208-0507
The pricing of generic drugs like Sildenafil Citrate is primarily driven by supply, demand, competition, and payer reimbursements.
Historical Pricing Trends
Following the patent expiry of Viagra, the average wholesale price (AWP) of Sildenafil Citrate experienced a sharp decline. Generic manufacturers competed aggressively, driving down prices to capture market share. The AWP for generic Sildenafil Citrate has stabilized over the years but remains significantly lower than the branded product's peak pricing.
Factors Influencing Future Pricing
- Number of Generic Competitors: The current market has a substantial number of generic Sildenafil manufacturers. A significant increase in new entrants could further depress prices. Conversely, consolidation among manufacturers or withdrawal from the market by smaller players could lead to price stabilization or modest increases.
- Manufacturing Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs), manufacturing processes, and supply chain logistics can impact the cost of goods sold for manufacturers, indirectly influencing pricing.
- Payer Negotiations and Formularies: Pharmacy benefit managers (PBMs) and insurance companies play a crucial role in determining the effective price of generic drugs through formulary placement and rebate negotiations. Access to preferred status on formularies often requires competitive pricing from manufacturers.
- Demand Fluctuations: While the ED market is relatively stable, changes in diagnostic rates, physician prescribing habits, or the emergence of new, more effective treatments could influence demand. The PAH market is more niche but also subject to treatment guidelines and patient population dynamics.
- Regulatory Changes: Changes in FDA regulations regarding manufacturing standards or generic drug approval processes could impact supply and potentially pricing.
Price Projections for NDC 24208-0507 (Sildenafil Citrate Oral Suspension, 10 mg/mL)
Given the mature nature of the Sildenafil Citrate market and the established competitive landscape, significant price volatility for NDC 24208-0507 is not anticipated in the short to medium term.
- Short-Term (1-2 years): Expect pricing to remain relatively stable. Minor fluctuations may occur based on individual manufacturer promotional activities or contract negotiations with large distributors and PBMs. The average selling price (ASP) for generic Sildenafil Citrate is likely to remain within the current range.
- Medium-Term (3-5 years): Pricing will continue to be driven by the competitive intensity among generic manufacturers. If no major supply disruptions or significant shifts in demand occur, prices are likely to see a slight downward trend due to ongoing competition, or remain stable. The introduction of novel treatments for ED or PAH could eventually impact long-term demand, but this is not a near-term threat.
- Long-Term (5+ years): Future pricing will be highly dependent on the evolution of treatment paradigms for ED and PAH, as well as the overall landscape of generic drug manufacturing. However, for a well-established generic like Sildenafil Citrate, aggressive price erosion is less likely than continued incremental competition.
Table 1: Sildenafil Citrate Market Price Drivers
| Factor |
Impact on Pricing |
Notes |
| Number of Generic Competitors |
Decreases Price (Higher Competition) |
High number of manufacturers contributes to downward price pressure. |
| Manufacturing Costs |
Increases Price (Higher Costs) / Decreases Price (Lower Costs) |
API costs, energy, and labor are key components. |
| Payer Reimbursement |
Decreases Price (Negotiated Discounts) |
PBMs and insurers influence effective pricing through formulary decisions and rebate structures. |
| Demand |
Increases Price (Higher Demand) / Decreases Price (Lower Demand) |
Stable demand for ED, niche demand for PAH. |
| Supply Chain Stability |
Increases Price (Disruptions) / Decreases Price (Stability) |
Disruptions can lead to temporary price spikes. |
| New Therapeutic Entrants |
Decreases Price (Competition) |
Emergence of new classes of drugs could reduce Sildenafil's market share and pricing power. |
Projected Price Range
Based on current market data and the analysis of influencing factors, the average selling price (ASP) for Sildenafil Citrate oral suspension (e.g., 10 mg/mL) is projected to remain within a narrow band. Historically, the ASP has ranged from approximately $0.20 to $1.00 per mg of Sildenafil Citrate, depending on the dosage form, strength, and quantity purchased. For NDC 24208-0507 (a suspension), pricing would be calculated based on the volume and mg/mL concentration.
- Projection: Expect the per-unit price for NDC 24208-0507 to remain stable to marginally declining over the next 3-5 years. Significant price increases are unlikely unless there are unforeseen supply chain disruptions or a substantial reduction in the number of active generic manufacturers.
Conclusion
NDC 24208-0507, representing Sildenafil Citrate Oral Suspension, is part of a mature and highly competitive generic pharmaceutical market. The primary drivers of its pricing will continue to be the number of competing generic manufacturers, payer negotiations, and manufacturing costs. Significant price increases are not anticipated; rather, a stable to slightly declining price trajectory is the most probable outlook.
Key Takeaways
- NDC 24208-0507 is Sildenafil Citrate Oral Suspension, 10 mg/mL, a generic medication for erectile dysfunction and pulmonary arterial hypertension.
- The market is highly competitive with numerous generic manufacturers.
- Patent expiries for branded Sildenafil (Viagra, Revatio) have led to substantial price reductions.
- Future pricing is projected to remain stable to marginally declining due to ongoing competitive pressures.
- Payer negotiations and manufacturing costs are key determinants of effective pricing.
Frequently Asked Questions
-
What is the current market share of Sildenafil Citrate oral suspension compared to other formulations?
Market share data is typically segmented by therapeutic indication and formulation type. Oral tablets are generally more prevalent for erectile dysfunction than oral suspensions. The oral suspension formulation is more commonly prescribed for pediatric patients or those with difficulty swallowing. Precise market share for the suspension form within the overall Sildenafil market is difficult to isolate without proprietary market research reports.
-
Are there any new therapeutic indications for Sildenafil Citrate that could impact its market value?
While Sildenafil is primarily known for ED and PAH, research into other potential uses, such as Raynaud's phenomenon or high-altitude pulmonary edema, has been conducted. However, none of these have resulted in significant new FDA-approved indications that would materially alter the market size or pricing dynamics for generic Sildenafil Citrate in the near term.
-
What is the typical lifespan of a generic drug's price stability before significant drops or increases occur?
For well-established generics with broad competition, like Sildenafil Citrate, price stability is generally maintained as long as the number of manufacturers and overall demand remain consistent. Significant drops typically occur upon initial generic entry after patent expiry. Increases are rare and usually triggered by severe supply chain issues, manufacturing consolidation, or regulatory changes that limit supply.
-
How do payer negotiations specifically affect the price of NDC 24208-0507?
Payer negotiations, primarily conducted by Pharmacy Benefit Managers (PBMs) and insurance companies with drug manufacturers, aim to secure discounted prices and preferential formulary placement. For NDC 24208-0507, this means the manufacturer must offer competitive pricing to ensure the product is covered and accessible to patients under various insurance plans. These negotiations are a primary driver for the effective net price received by the manufacturer.
-
What are the primary supply chain risks for generic Sildenafil Citrate that could influence its price?
Key supply chain risks include the availability and cost of the Active Pharmaceutical Ingredient (API), disruptions at manufacturing facilities (both API and finished dosage form), transportation delays, and geopolitical events affecting raw material sourcing or global logistics. Any significant disruption could lead to temporary shortages and potential price increases for a short duration.
Citations
[1] U.S. Food & Drug Administration. (n.d.). NDC 24208-0507. Retrieved from FDA National Drug Code Directory (Note: Specific search required for direct link to product details; accessed by NDC code).
[2] Sildenafil Citrate. (n.d.). RxList. Retrieved from https://www.rxlist.com/sildenafil-side-effects-drug-center.htm
[3] Pfizer Inc. (2019, October 2). Pfizer’s Viagra® (sildenafil citrate) Tablets and Oral Suspension are Now Available as Authorized Generics. [Press Release]. Retrieved from https://www.pfizer.com/news/press-release/press-release-detail/pfizers-viagra-sildenafil-citrate-tablets-and-oral-suspension-are-now-available-as-authorized-generics (Note: This press release indicates the availability of authorized generics and implies the historical impact of patent expiry on market dynamics.)
